BackgroundMultidrug-resistant Klebsiella pneumoniae represents a significant challenge in healthcare settings, prompting numerous studies on the rapid detection of antimicrobial resistance. Mass spectrometry has been recently integrated into routine laboratory diagnostics, providing highly sensitive results for pathogen identification. Furthermore, previously published studies have demonstrated its potential application in predicting antimicrobial resistance.Materials and methodsThe study collected 686 clinical isolates of K. pneumoniae from three Italian hospitals and used their MALDI-TOF mass spectra as input to machine learning models for predicting susceptibility profiles to amikacin and meropenem, which were selected as the most represented antibiotic molecules within the aminoglycoside and carbapenem classes, commonly used for the treatment of K. pneumoniae infections. After preprocessing, K. pneumoniae spectra were fed to machine learning classifiers within a nested cross-validation framework. Several performance metrics were computed to compare models and identify the most appropriate one for each antibiotic. Given the multicentric nature of the study, a batch-effect correction step was applied to reduce site-specific variability using the in-house developed Python package combatlearn (available on GitHub: https://github.com/EttoreRocchi/combatlearn).ResultsThe XGBoost model achieved the best performance for both antibiotics (AUROC = 0.822 +/- 0.028 for amikacin; AUROC = 0.887 +/- 0.019 for meropenem). A per-site performance analysis revealed that, while performances' variability was inherently linked to each center's sample size, combatlearn-based harmonization effectively aligned mean AUROC values across sites.ConclusionsOur study demonstrates the capability of MALDI-TOF mass spectra to predict amikacin and meropenem resistance in K. pneumoniae directly from clinical spectra, supporting its potential as a rapid and cost-effective approach for both antimicrobial resistance surveillance through machine learning models and clinical decision support in routine microbiology practice.

Combining mass spectrometry and machine learning models for predicting Klebsiella pneumoniae antimicrobial resistance: a multicenter experience from clinical isolates in Italy

Cento, Valeria;
2026-01-01

Abstract

BackgroundMultidrug-resistant Klebsiella pneumoniae represents a significant challenge in healthcare settings, prompting numerous studies on the rapid detection of antimicrobial resistance. Mass spectrometry has been recently integrated into routine laboratory diagnostics, providing highly sensitive results for pathogen identification. Furthermore, previously published studies have demonstrated its potential application in predicting antimicrobial resistance.Materials and methodsThe study collected 686 clinical isolates of K. pneumoniae from three Italian hospitals and used their MALDI-TOF mass spectra as input to machine learning models for predicting susceptibility profiles to amikacin and meropenem, which were selected as the most represented antibiotic molecules within the aminoglycoside and carbapenem classes, commonly used for the treatment of K. pneumoniae infections. After preprocessing, K. pneumoniae spectra were fed to machine learning classifiers within a nested cross-validation framework. Several performance metrics were computed to compare models and identify the most appropriate one for each antibiotic. Given the multicentric nature of the study, a batch-effect correction step was applied to reduce site-specific variability using the in-house developed Python package combatlearn (available on GitHub: https://github.com/EttoreRocchi/combatlearn).ResultsThe XGBoost model achieved the best performance for both antibiotics (AUROC = 0.822 +/- 0.028 for amikacin; AUROC = 0.887 +/- 0.019 for meropenem). A per-site performance analysis revealed that, while performances' variability was inherently linked to each center's sample size, combatlearn-based harmonization effectively aligned mean AUROC values across sites.ConclusionsOur study demonstrates the capability of MALDI-TOF mass spectra to predict amikacin and meropenem resistance in K. pneumoniae directly from clinical spectra, supporting its potential as a rapid and cost-effective approach for both antimicrobial resistance surveillance through machine learning models and clinical decision support in routine microbiology practice.
2026
Amikacin
Antimicrobial resistance
Batch-effect correction
Harmonization
Klebsiella pneumoniae
MALDI-TOF
Machine learning
Mass spectrometry
Meropenem
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11699/106468
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact